ammonium hydroxide has been researched along with Abdominal Migraine in 5 studies
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although patients diagnosed as having migraine, have been studied extensively, there is no definite proof of a primary biochemical abnormality which is of significance in the pathogenesis of migraine." | 1.26 | Further observation on the possible relationship between migraine and serum ammonia levels. ( Bruyn, GW; de Bruijn, JG; Klawans, HL, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stankewitz, A | 1 |
| Voit, HL | 1 |
| Bingel, U | 1 |
| Peschke, C | 1 |
| May, A | 1 |
| Rivas Nuñez, CJ | 1 |
| Fernandez Martin, F | 1 |
| de Bruijn, JG | 1 |
| Bruyn, GW | 1 |
| Klawans, HL | 1 |
| Gilchrist, JM | 1 |
| Coleman, RA | 1 |
| Szám, I | 1 |
| Eckhardt, S | 1 |
| Németh, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of the Tx360 Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine: A Double-blind Placebo-controlled Study[NCT01709708] | Phase 4 | 41 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of acute medications used during Treatment period (6 weeks) and Follow-Up (4 weeks) (Group A vs. Group B). (NCT01709708)
Timeframe: 10 Weeks
| Intervention | Number of medications used (Mean) |
|---|---|
| Marcaine | 29.3 |
| Saline | 47.4 |
Number of adverse events over the entire length of study (Group A vs. Group B). (NCT01709708)
Timeframe: 34 weeks
| Intervention | Number of Adverse Events (Mean) |
|---|---|
| Marcaine | 7.67 |
| Saline | 5.29 |
Compare percentage change in Numeric Rating Scale (NRS) score from Before Procedure to 15-Minutes, Before Procedure to 30-Minutes, Before Procedure to 24-Hours After Procedure for all 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. (NCT01709708)
Timeframe: 15 Minutes Post Treatment, 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
| Intervention | percentage of change (Mean) | ||
|---|---|---|---|
| 15 Minutes Post Treatment | 30 Minutes Post Treatment | 24 Hours Post Treatment | |
| Marcaine | -23.3 | -27.7 | -15.5 |
| Saline | -4.31 | -5.41 | 13.5 |
"Total Headache Impact Test (HIT-6) scores Pre-Treatment at Visit 2 vs. Post-Treatment (following final treatment), and at 1-Month Post-Treatment (Group A vs. Group B). HIT-6 is a series of 6 likert scale questions ranging from 1 to 5 with 1 being never and 5 being always. The HIT-6 answer options are weighted as follows: Never (1) = 6 points each, Rarely (2) = 9 points each, Sometimes (3) = 10 points each, Very often (4) = 11 points each, Always (5) = 13 points each. The total score for the HIT-6 ranges from 36 (subject answers all 6 questions as Never) to 78 subject answers all 6 questions as Always), with higher total scores indicating more impact than lower scores, i.e., headaches cause greater impact on the subject's life." (NCT01709708)
Timeframe: 10 Weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | 1-Month Post-Treatment | |
| Marcaine | 64.36 | 59.85 | 59.23 |
| Saline | 64 | 62.5 | 61.92 |
Compare change in the number of migraine headache days per month reported in Baseline Period Diary vs. Treatment Period Diary vs. Post-Treatment Period Diary. (NCT01709708)
Timeframe: 12 Weeks
| Intervention | Migraine headache days per month (Mean) | ||
|---|---|---|---|
| Baseline | Treatment | Post Treatment | |
| Marcaine | 15.0 | 12.3 | 10.8 |
| Saline | 15.8 | 12.2 | 11.3 |
Compare Modified Pain Characteristic Questionnaire scores Before Procedure vs. 24-Hour After Procedure, Before Procedure vs. 1-Month Follow Up, and Before Procedure vs. 6-Month Follow Up (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). The modified pain characteristic questionnaire is a series of 11 questions on a likert scale ranging from 0 to 10 with 0 being no pain or does not interfere and 10 being worst pain or completely interferes. Percentage questions range from 0 to 100. (NCT01709708)
Timeframe: Before Treatment, 24 Hours After Treatment, 1 Month Post Treatment, and 6 Months Post Treatment
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Worst Pain Question: Before Treatment | Worst Pain Question: 24 Hours After Treatment | Worst Pain Question: 1 Month Post Treatment | Worst Pain Question: 6 Months Post Treatment | Least Pain Question: Before Treatment | Least Pain Question: 24 Hours After Treatment | Least Pain Question: 1 Month Post Treatment | Least Pain Question: 6 Months Post Treatment | Average Pain Question: Before Treatment | Average Pain Question: 24 Hours After Treatment | Average Pain Question: 1 Month Post Treatment | Average Pain Question: 6 Months Post Treatment | Percent Relief Question: Before Treatment | Percent Relief Question: 24 Hours After Treatment | Percent Relief Question: 1 Month Post Treatment | Percent Relief Question: 6 Months Post Treatment | General Activity Question: Before Treatment | General Activity Question: 24 Hours After Treatmen | General Activity Question: 1 Month Post Treatment | General Activity Question: 6 Months Post Treatment | Mood Interference Question: Before Treatment | Mood Interference Question: 24 Hours After Treatme | Mood Interference Question: 1 Month Post Treatment | Mood Interference Question: 6 Months Post Treatmen | Walking Ability Question: Before Treatment | Walking Ability Question: 24 Hours After Treatment | Walking Ability Question: 1 Month Post Treatment | Walking Ability Question: 6 Months Post Treatment | Normal Work Question: Before Treatment | Normal Work Question: 24 Hours After Treatment | Normal Work Question: 1 Month Post Treatment | Normal Work Question: 6 Months Post Treatment | Relationships Question: Before Treatment | Relationships Question: 24 Hours After Treatment | Relationships Question: 1 Month Post Treatment | Relationships Question: 6 Months Post Treatment | Sleep Interference Question: Before Treatment | Sleep Interfere Question: 24 Hours After Treatment | Sleep Interferenc Question: 1 Month Post Treatment | Sleep Interference Question: 6 Months Post Treatme | Enjoyment Question: Before Treatment | Enjoyment Question: 24 Hours After Treatment | Enjoyment Question: 1 Month Post Treatment | Enjoyment Question: 6 Months Post Treatment | |
| Marcaine | 4.75 | 4.36 | 4.56 | 4.27 | 2.01 | 1.77 | 1.88 | 1.68 | 3.39 | 3.07 | 3.36 | 2.86 | 41.3 | 46.0 | 46.3 | 34.7 | 2.49 | 2.31 | 2.64 | 2.68 | 2.57 | 2.42 | 2.96 | 3.18 | 0.63 | 0.54 | 0.80 | 0.45 | 2.53 | 2.21 | 2.52 | 2.59 | 2.00 | 1.96 | 2.36 | 2.05 | 2.29 | 1.89 | 1.92 | 1.55 | 2.81 | 2.58 | 2.64 | 3.18 |
| Saline | 6.15 | 6.16 | 5.64 | 5.88 | 2.50 | 2.43 | 2.64 | 2.88 | 4.33 | 4.27 | 3.91 | 4.00 | 29.2 | 29.8 | 21.0 | 18.6 | 3.50 | 3.64 | 3.91 | 4.00 | 3.78 | 4.19 | 3.82 | 5.71 | 1.27 | 1.24 | 0.55 | 0.43 | 3.49 | 3.63 | 3.45 | 3.71 | 3.47 | 3.90 | 3.09 | 3.86 | 2.68 | 2.85 | 2.55 | 3.14 | 3.12 | 3.34 | 3.09 | 4.00 |
Compare Numeric Rating Scale (NRS) scores Before Procedure,15-Minute Post Treatment, 30-Minutes Post Treatment, 24-Hour Post Treatment for all 12 treatments (Marcaine vs. Saline). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. For each individual time point, all 12 treatments were averaged for that time point and a single value was used for comparison between the two groups. (NCT01709708)
Timeframe: 6 Weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Before Procedure | 15 Minutes Post Treatment | 30 Minutes Post Treatment | 24 Hours Post Treatment | |
| Marcaine | 3.18 | 2.53 | 2.41 | 2.85 |
| Saline | 3.78 | 3.51 | 3.45 | 4.20 |
Satisfaction scores Visit 2 vs. following treatment (Treatment 12) and at 1-Month Post-Treatment (Group A vs. Group B). Satisfaction scores are a likert scale ranging from 1 to 5 with 1 being complete dissatisfaction and 5 being complete satisfaction. (NCT01709708)
Timeframe: 10 Weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Visit 2 | Following treatment (Treatment 12) | 1-Month Post-Treatment | |
| Marcaine | 3.52 | 3.55 | 3.57 |
| Saline | 3.00 | 2.50 | 2.64 |
Compare 24-Hour After Procedure Patient's Global Impression of Change (PGIC) score for 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). PGIC is a likert scale ranging from 1 to 7 with 1 being very much improved and 7 being very much worse. (NCT01709708)
Timeframe: 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 30 Minutes Post Treatment | 24 Hours Post Treatment | |
| Marcaine | 3.00 | 3.08 |
| Saline | 3.72 | 3.88 |
1 review available for ammonium hydroxide and Abdominal Migraine
| Article | Year |
|---|---|
[Biochemical aspects of migraine].
Topics: 5-Hydroxytryptophan; Age Factors; Ammonia; Blood Platelet Disorders; Female; Humans; Menstruation; M | 1975 |
4 other studies available for ammonium hydroxide and Abdominal Migraine
| Article | Year |
|---|---|
A new trigemino-nociceptive stimulation model for event-related fMRI.
Topics: Adult; Ammonia; Brain Stem; Female; Humans; Irritants; Magnetic Resonance Imaging; Male; Migraine Di | 2010 |
Further observation on the possible relationship between migraine and serum ammonia levels.
Topics: Adult; Ammonia; Humans; Migraine Disorders | 1976 |
Ornithine transcarbamylase deficiency: adult onset of severe symptoms.
Topics: Adult; Ammonia; Brain Diseases, Metabolic; Female; Hemiplegia; Heterozygote; Humans; Mental Disorder | 1987 |
[Further studies on clopamide].
Topics: Adult; Amides; Ammonia; Clopamide; Diuretics; Female; Humans; Hypertension; Lymphedema; Male; Middle | 1970 |